Navigation Links
YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
Date:12/10/2009

and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 5,000 patients reported as having been treated with nimotuzumab worldwide to date, rare incidents of Grade IV radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not l
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Biosciences Acquires Protein Forest
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
4. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
5. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
6. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
7. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
8. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
9. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
10. YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... this month, a report was created by Colorado ... Force on the performance of vehicles using an eco-friendly, ... fuel made from mustard seeds, offered great potential as ... friendly future. In fact, every branch of the U.S. ... foreign oil over the next few years. They will ...
(Date:8/28/2014)... New York, NY (PRWEB) August 28, 2014 ... has renewed its long term partnership with PTI ... to provide clients with state of the art leak ... state of the art instruments currently available. As part ... a new High Voltage Leak Detection Instrument ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics ... in metabolic disorders, announced today that it has filed ... Securities and Exchange Commission (SEC) relating to the proposed ... The number of shares to be offered and the ... determined. Citigroup and Cowen and Company will ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... MONTVALE, N.J., May 13 Synvista Therapeutics,Inc. (Amex: ... a 160-patient Phase 2 study,of alagebrium in patients with ... A.G.E. [Advanced Glycation End Product],Breaker Alagebrium in Diastolic Heart ... the effect of six months,of oral treatment with 400mg ...
... Yields First Milestone, NEW YORK, May 13 ... pre-disease collection, processing and long-term,storage of adult stem cells ... been secured for a new stem cell collection center ... Smith, MD MBA, NeoStem,s Chairman and Chief Executive Officer,commented: ...
... May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... Phase 2 study of subcutaneously,administered LHRH antagonist ... (BPH", has been accepted for publication in ...
Cached Biology Technology:Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 2Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 3Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure 4NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 2AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 3AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 4AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 5AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal 6
(Date:8/28/2014)... MARC (Maximizing Access to Research Careers) Program has announced ... Human Genetics from October 18 22, 2014 in ... promote the entry of students, post doctorates and scientists ... science community and to encourage the participation of young ... This year MARC conferred 16 awards totaling $29,600., The ...
(Date:8/28/2014)... Researchers at the University of Minnesota have developed ... to be used for muscle regeneration research as well ... FSHD. , The research is published in the current ... There is no treatment for FSHD, which is thought ... muscular dystrophy. FSHD is an unusual genetic disorder because, ...
(Date:8/28/2014)... Ga. The support of peer groups and ... breastfeeding programs, according to recent University of Georgia ... in the Athens-Clarke County area determined that role ... outcomes of mothers of infants. , "Mothers who ... successful at breastfeeding," said study co-author Alex Anderson, ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2
... which they can pass on to humans. But now research ... Research says that pigs get HEV early enough to minimise ... worry about would occur if the infection rate in pigs ... chance pigs will pass on HEV to humans at slaughter. ...
... Dr Pep Canadell, from the Global Carbon Project and CSIRO ... that tropical deforestation releases 1.5 billion tonnes of carbon each ... accounts for nearly 20 per cent of carbon emissions due ... estimated 87 to 130 billion tonnes of carbon by 2100, ...
... grazing normally on algae in the rocky intertidal zone of ... by a parasite. But the better news is, according to ... might have more to eat if plenty of your neighbors ... of the National Academy of Sciences Early Edition ( http://www.pnas.org/papbyrecent.shtml ...
Cached Biology News:Confirmed -- deforestation plays critical climate change role 2Parasites' impact goes beyond host to affect ecosystem 2Parasites' impact goes beyond host to affect ecosystem 3
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
Biology Products: